WITHIN THE HMO INDUSTRY, Kaiser Permanente is highly respected for its thorough research into the clinical efficacy and economic cost of new healthcare technologies. That is the reason why Kaiser’s decision to adopt NeoPath, Inc.’s automated cytology technology for primary screening of Pap smears is getting widespread attention within the laboratory community. Coupled with a similar […]
- "Automated Cytology Update"
Kaiser Plans Widespread Use For Pap Technology
Actual clinical experience with AutoPap System in QC and primary screening proves encouraging
- By Robert Michel
- > From the Volume V No. 15 - November 9, 1998 Issue
